Document Detail


Effects of zoledronate in the repair of chronically infarcted rat myocardium.
MedLine Citation:
PMID:  21052019     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
Zoledronate (Zol), one of the class of bisphophonate drugs, is commonly used to treat postmenopausal osteoporosis. Treatment of liposomal bisphosphonates has been shown to worsen myocardial infarct repair in an experimental model. The purpose of this study was to investigate the effect of Zol in the repair of chronically infarcted myocardium without liposomal encapsulation to mimic the clinical setting. Zol (20 μg/kg, a dose known to treat experimental osteoporosis in rats, n = 15) was administered subcutaneously to female Sprague-Dawley rats 1 day before coronary artery ligation. Rats receiving phosphate-buffered saline (n = 12) were used as controls. Left ventricular function, infarct size, and remodeling were studied at 4 weeks postinfarction. Zol pretreatment did not affect left ventricular ejection fraction in hearts with myocardial infarction (49.5 ± 1.4% in Zol; 50.6 ± 2.1% in phosphate-buffered saline). Infarct size was similar in Zol versus untreated hearts (34.2% ± 2.9% in Zol; 33.4% ± 2.9% in phosphate-buffered saline). Left ventricular cavity volume and circumference, infarct thickness, and expansion index were comparable between the groups. To investigate a potential effect of Zol on tissue macrophage infiltration after myocardial infarction, heart specimens were harvested 48 hours postinfarction and sections were immunostained with CD68 antibody, a macrophage-specific marker. Results of macrophage immunostaining revealed that the level of tissue macrophage infiltration was similar between groups. In conclusion, administration of Zol before myocardial infarction had no adverse effects on cardiac contractile function, infarct size, or remodeling. These results suggest that treatment of Zol given before the onset of myocardial infarction does not cause worsening of infarct repair.
Authors:
Hyosook Hwang; Sharon L Hale; Justin Leeka; Robert A Kloner
Related Documents :
2959259 - Myocardial contractility and left ventricular myosin isoenzyme pattern in cardiac hyper...
17030559 - Differential regulation of the nitric oxide-cgmp pathway exacerbates postischaemic hear...
7639329 - Collagen remodeling after myocardial infarction in the rat heart.
17890289 - Comparative effects of acute vs. chronic oral amiodarone treatment during acute myocard...
25478499 - Single beat determination of intraventricular systolic dyssynchrony in patients with at...
8762209 - Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously h...
1678029 - High breath pentane concentrations during acute myocardial infarction.
23302959 - Cardiac output, at rest and during exercise, before and during myocardial ischemia, rep...
21807379 - Frontal subcortical ischemia is crucial for post stroke cognitive impairment.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  56     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2011-04-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  604-9     Citation Subset:  IM    
Affiliation:
The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardioprotective effects of 2-octynyladenosine (YT-146) in ischemic/reperfused rat hearts.
Next Document:  Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensiv...